Genzyme Says Health Canada Approves Lemtrada For Multiple Sclerosis

(RTTNews) - Genzyme, a Sanofi company (SNYNF, SNY), Friday said Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis or RRMS, with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.

Lemtrada is supported by a comprehensive clinical development program that involved nearly 1,500 patients and 5,400 patient-years of follow-up.

The approval in Canada follows the recent approval of Lemtrada in the European Union.

Marketing applications for Lemtrada are also under review in various other countries, including the U.S. and Mexico.

Over 2.3 million people worldwide have been diagnosed with MS, including around 100,000 people in Canada.